The 86th Scientific Sessions of the American Diabetes Association (ADA 2026)

New Orleans, Louisiana, US 05 June 2026 - 08 June 2026

Triple win for fixed-dose combo in T2D

08 Jul 2026 by

A fixed-dose combination of the novel amylin receptor agonist cagrilintide and the approved GLP-1 receptor agonist semaglutide (CagriSema) yields better HbA_1c control and weight loss in patients with type 2 diabetes (T2D) than either therapy alone or placebo in three phase III trials from the global REIMAGINE programme presented at ADA 2026. The benefits also extend to patients on insulin therapy.

Triple win for fixed-dose combo in T2D

08 Jul 2026

Orforglipron promotes weight loss across all menopausal stages

27 Jun 2026 by

Once-daily treatment with the highest orforglipron dose is associated with significant reductions in body weight and waist circumference at week 72 in women with obesity or overweight, regardless of menopausal status, according to a post hoc analysis of the phase III ATTAIN-1 and -2 trials presented at ADA 2026.

Orforglipron promotes weight loss across all menopausal stages

27 Jun 2026

Novel petrelintide shows promise for obesity treatment

25 Jun 2026 by

Treatment with a once-weekly injectable petrelintide, a novel human amylin analogue, yields up to 10.7 percent weight loss through week 42 in adults with obesity or overweight, according to the phase II ZUPREME-1 trial presented at ADA 2026.

Novel petrelintide shows promise for obesity treatment

25 Jun 2026

Berobenatide a promising addition to the current GLP-1 RA roster

24 Jun 2026 by

In the phase II VESPER-2 trial, the investigational injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) berobenatide shows robust reductions in weight and HbA1c in adults with obesity/overweight and type 2 diabetes (T2D).

Berobenatide a promising addition to the current GLP-1 RA roster

24 Jun 2026

Adjunctive HBOT beneficial for DFUs

23 Jun 2026 by

A meta-analysis presented at ADA 2026 supports the benefits of hyperbaric oxygen therapy (HBOT) for ulcer healing and reducing the risk of major amputation in individuals with diabetic foot ulcers (DFUs).

Adjunctive HBOT beneficial for DFUs

23 Jun 2026

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026 by

A recent study comparing dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with orforglipron, an oral nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist (RA), has found superior glycaemic control and weight loss with the latter.

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026 by

The use of mazdutide among adults with obesity results in a clinically significant weight reduction and improvements in cardiometabolic risk factors, with an acceptable safety profile, as shown in the phase 3 GLORY-2 trial presented at ADA 2026.

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026 by

In a post hoc analysis of the phase III MAESTRO-NASH trial presented at ADA 2026, systemic thyroid function remained stable with resmetirom, supporting its extrahepatic safety in individuals with metabolic dysfunction-associated steatohepatitis (MASH).

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

18 Jun 2026 by

For individuals with type 2 diabetes (T2D) that is inadequately controlled by diet and exercise alone, once-weekly administration of the triple hormone receptor agonist retatrutide helps improve glycaemic control, and this benefit is accompanied by substantial weight reduction, as shown in the phase III TRANSCEND-T2D-1 study.

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

18 Jun 2026

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

17 Jun 2026 by

Daily treatment with oral orforglipron, when added to titrated insulin glargine, has been shown to be beneficial in individuals with inadequately controlled type 2 diabetes (T2D) in the phase 3 ACHIEVE-5 trial.

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

17 Jun 2026